A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis

NCT01194414 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1262

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: tocilizumab SC
DRUG: tocilizumab IV
DRUG: placebo to tocilizumab SC
DRUG: placebo to tocilizumab IV
DRUG: Disease-modifying antirheumatic drugs (DMARDs)

Sponsor

Hoffmann-La Roche